TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medivir AB ( (SE:MVIR) ) has provided an announcement.
Medivir AB has announced a new share issue with preferential rights for existing shareholders, aiming to raise approximately SEK 151 million, with the possibility of an additional SEK 20 million through an over-allotment issue. This initiative is fully secured by existing shareholders and external investors, and the disclosure document has been registered with the Swedish Financial Supervisory Authority. The move is expected to bolster Medivir’s financial position, supporting its ongoing drug development efforts and potentially enhancing its market standing.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir is a pharmaceutical company focused on developing innovative cancer drugs, particularly where there is a high unmet medical need. The company is working on fostroxacitabine bralpamide (fostrox), a drug candidate aimed at treating liver cancer cells selectively while minimizing side effects. Medivir operates through collaborations and partnerships and is listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 584,116
Technical Sentiment Signal: Sell
Current Market Cap: SEK49.57M
For detailed information about MVIR stock, go to TipRanks’ Stock Analysis page.